Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company focusing on neuromuscular and cardiac diseases, has granted 116,150 restricted stock units (RSUs) to four new employees. The RSUs will vest equally over four years, with 25% vesting on each anniversary of the grant date.
The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.
Solid Biosciences (Nasdaq: SLDB), un'azienda di medicinali genetici di precisione che si concentra su malattie neuromuscolari e cardiache, ha concesso 116.150 unità di azioni restritte (RSU) a quattro nuovi dipendenti. Le RSU matureranno in modo uniforme nell'arco di quattro anni, con il 25% che matura ad ogni anniversario della data di concessione.
Le assegnazioni azionarie sono state emesse ai sensi del Piano di Incentivi Azionari per l'Induzione 2024 e sono conformi alla Nasdaq Listing Rule 5635(c)(4), fungendo da incentivo all'accettazione dell'impiego.
Solid Biosciences (Nasdaq: SLDB), una empresa de medicamentos genéticos de precisión centrada en enfermedades neuromusculares y cardíacas, ha otorgado a cuatro nuevos empleados 116.150 unidades de acciones restringidas (RSU). Las RSU se consolidarán de forma uniforme durante cuatro años, con un 25% consolidándose en cada aniversario de la fecha de concesión.
Las recompensas de acciones fueron emitidas bajo el Plan de Incentivo de Acciones por Inducción 2024 y cumplen con la Nasdaq Listing Rule 5635(c)(4), sirviendo como inducción para la aceptación del empleo.
Solid Biosciences (나스닥: SLDB), 정확한 유전자 의약품을 다루는 신경근육 및 심장 질환에 집중하는 회사가 네 명의 신입 직원에게 116,150주 제한 주식(RSU)를 부여했습니다. 이 RSU는 4년 동안 균등하게 귀속되며, 매년 기산일 25%가 귀속됩니다.
주식 보상은 회사의 2024년 유도형 주식 인센티브 계획에 따라 발행되었으며 Nasdaq Listing Rule 5635(c)(4)을 준수하여 고용 수락에 대한 인센턴스로 작용합니다.
Solid Biosciences (Nasdaq : SLDB), une société de médicaments génétiques de précision axée sur les maladies neuromusculaires et cardiaques, a accordé à quatre nouveaux employés 116 150 unités d’options d’actions restreintes (RSU). Les RSU seront acquises de manière égale sur quatre ans, soit 25 % d’acquisition à chaque anniversaire de la date de concession.
Les attributions d’actions ont été émises dans le cadre du Piano d’Incitation d’Actions 2024 et respectent la Nasdaq Listing Rule 5635(c)(4), servant d’incitation à l’embauche.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen für präzise Gentherapien, das sich auf neuromuskuläre und kardiovaskuläre Erkrankungen konzentriert, hat vier neuen Mitarbeitenden 116.150 Restricted Stock Units (RSUs) gewährt. Die RSUs vesten gleichmäßig über vier Jahre, wobei jeweils 25% am Jahrestag des Gewährungsdatums vesten.
Die Aktienzuteilungen wurden im Rahmen des 2024 Inducement Stock Incentive Plan des Unternehmens ausgegeben und entsprechen der Nasdaq Listing Rule 5635(c)(4), dienen als Anreiz zur Annahme der Beschäftigung.
Solid Biosciences (ناسداك: SLDB)، شركة أدوية جينية دقيقة تركز على أمراض الأعصاب والعضلة القلبية، منحت إلى أربعة موظفين جدد 116,150 وحدة أسهم مقيدة (RSUs). ستتكوّن RSUs بالتساوي على مدى أربع سنوات، مع تحقّق 25% في كل ذكرى تاريخ المنحة.
تم إصدار جوائز الأسهم بموجب خطة حوافز الأسهم للترغيب في التوظيف 2024 وتلتزم بقاعدة إدراج ناسداك 5635(c)(4)، وتعمل كم حافز لقبول العمل.
Solid Biosciences (纳斯达克股票代码: SLDB)，一家专注于神经肌肉和心脏疾病的精准基因药物公司，已向四名新员工授予 116,150份受限股票单位（RSUs）。这些 RSU 将在四年内均匀归属，授予日周年时各占 25%。
此次股权奖励基于公司 2024 Inducement Stock Incentive Plan 发出，符合纳斯达克上市规则 5635(c)(4)，作为雇佣接受的诱因。
- None.
- None.
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 116,150 restricted stock units (“RSUs”) to four newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many RSUs did Solid Biosciences (SLDB) grant to new employees in October 2025?
What is the vesting schedule for Solid Biosciences' (SLDB) October 2025 RSU grants?
Under which plan were the Solid Biosciences (SLDB) RSU grants issued?
What type of company is Solid Biosciences (SLDB)?
